Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Integrating budesonide-MMX into treatment algorithms for ulcerative colitis

A study in the latest Alimentary Pharmacology & Therapeutics reviews integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis.

News image

5-Aminosalicylates (5-ASA) are first-line treatment for mild–moderately active ulcerative colitis.

When 5-ASAs fail, systemic corticosteroids have been the standard next step.

Due to the significant side effect profile of systemic corticosteroids, alternative options in the treatment algorithm after 5-ASA failures are needed.

Budesonide-Multi-Matrix System (MMX) is a novel oral formulation of budesonide that uses colonic release MMX technology to extend release of the drug to the colon.

Now that budesonide-MMX has been approved for use in some countries, and pending in others there is a need to understand its position in the treatment algorithm for ulcerative colitis.

Dr Danese and colleagues from Italy reviewed the available literature for budesonide-MMX and incorporate it into the treatment algorithm for mild–moderate ulcerative colitis.

Safety data are reassuring, including those for steroid-related side effects
Alimentary Pharmacology & Therapeutics

The team reviewed the available efficacy and safety literature regarding budesonide-MMX, and compared to 5-ASAs and systemic corticosteroids.

In two large studies referred to as CORE (Colonic Release Budesonide trial), budesonide-MMX 9 mg daily was significantly more effective in achieving a combined end point of clinical and endoscopic remission than placebo in patients with mild–moderately active ulcerative colitis.

The researchers report that safety data are reassuring, with no clinically relevant differences between budesonide-MMX and placebo, including steroid-related side effects.

Dr Danese's team comments, "Budesonide-MMX 9 mg daily is an effective and safe treatment for induction in patients with mild–moderately active ulcerative colitis."

"At the current time, it should be considered in patients after 5-ASA failure and before systemic corticosteroids."

"Data are still needed to understand its role and dose beyond 8 weeks, and if it should be considered first line before 5-ASAs."

Aliment Pharmacol Ther 2014: 39(10): 1095–1103
29 April 2014

Go to top of page Email this page Email this page to a colleague

 03 August 2015

Advanced search
 03 August 2015 
Lack of response to therapy in severe ulcerative colitis
 03 August 2015 
Vaccinations and IBD
 03 August 2015 
Nutritional vs biological therapy in Crohn's
 31 July 2015 
Risk of hepatocellular carcinoma in chronic HCV with diabetes
 31 July 2015 
Prognostic index for hep C-related cirrhosis
 31 July 2015 
Reducing surgical site infection after stoma reversal
 30 July 2015 
Post-colonoscopy colorectal cancer rates
 30 July 2015 
Venous thromboembolism in colorectal surgery
 30 July 2015 
Saccharomyces boulardii for antibiotic-associated diarrhea
 29 July 2015 
Sitafloxacin-based triple therapy for H.pylori
 28 July 2015 
Lifestyle changes after colorectal cancer screening
 27 July 2015 
Fecal microbiota transplantation for severe C. difficile infection
 24 July 2015 
Causes of death in celiac disease
 23 July 2015 
Reduction in H. pylori prevalence
 22 July 2015 
Detection of esophageal eosinophilia and eosinophilic esophagitis
 21 July 2015 

Clinical outcomes for Barrett's esophagus neoplasia

 20 July 2015 
Certolizumab pegol for Crohn's disease
 17 July 2015 
Genetic variation and gastric cancer
 17 July 2015 
Colitis associated with anti-CTLA-4 therapy
 17 July 2015 

Sexual dysfunction after rectal cancer treatment

 16 July 2015 
Lynch syndrome screening by microsatellite instability
 16 July 2015 
Hormones and endometrial cancer in Lynch syndrome
 16 July 2015 
Relapse of IBD after discontinuation of anti-TNF therapy
 15 July 2015 
Risk prediction index for advanced colorectal cancer
 15 July 2015 
Aspergillus niger-derived enzymes
 15 July 2015 
Prophylactic omeprazole improves GI symptoms
 14 July 2015 
Combination therapies for chronic HCV
 14 July 2015 
Interferon- and ribavirin-free treatment regimen for HCV
 14 July 2015 
Cancer surveillance in ulcerative colitis
 13 July 2015 
Colon polyps in chronic inflammatory conditions of the colon
 13 July 2015 
Drugs and occult vs overt upper GI bleeds
 13 July 2015 
Anxiety and depression in functional GI disorders
 10 July 2015 
Daclatasvir in the treatment of chronic HCV
 10 July 2015 
Surveillance intervals to reduce colorectal cancer
 10 July 2015 
Stress and GI symptoms in IBD
 09 July 2015 
Opioid-induced esophageal dysfunction
 09 July 2015 
Marker of response to medical therapy in Crohn's
 09 July 2015 
Predictive factors for metastasis in colorectal cancer
 08 July 2015 

Nucleoside analogue therapy in HBeAg-negative chronic hepatitis B?

 08 July 2015 

Medical education in endoscopy training

 08 July 2015 
Chronic unexplained nausea and vomiting
 07 July 2015 
Anastomotic leak after elective surgery for colonic cancer
 07 July 2015 
Fecal transplantation for ulcerative colitis
 07 July 2015 
Obesity and risk of hepatocellular carcinoma
 06 July 2015 
Fecal microbiota transplantation
 06 July 2015 
Liver Failure–Sequential Organ Failure Scoring System
 06 July 2015 
Future colorectal surgery for metachronous cancers
 03 July 2015 
Tumors with mismatch-repair deficiency
 03 July 2015 
Aptitude of trainees in endoscopic ultrasonography
 03 July 2015 
Extracolonic pathologies in colorectal cancer
 02 July 2015 
Ulcerative colitis prognosis after thiopurines withdrawal
 02 July 2015 
Anastomotic leak and cancer cancer
 02 July 2015 
Health care use by IBD children
 01 July 2015 
Missed gastric cancers
 01 July 2015 
Oral mechanical bowel preparation
 01 July 2015 
Probiotics in IBD
 30 June 2015 
Split-dose preparations vs day-before bowel cleansing regimens
 30 June 2015 
Glucocorticoids and peptic ulcer bleeding
 30 June 2015 
NSAIDs and hearburn symptoms
 29 June 2015 
Prevention of pancreatitis after ERCP

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us